Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3974252 | Seminars in Fetal and Neonatal Medicine | 2014 | 5 Pages |
Abstract
SummaryThere have been tremendous advancements over the past three decades in prenatal screening for aneuploidy and we have changed our practice from screening by maternal age alone to ‘combined’ first trimester screening and circulating cell-free fetal DNA. We currently use the nuchal translucency and biochemical markers of free β-hCG and PAPP-A to determine the risk of fetal aneuploidy. The primary goal is to identify higher risk women for fetal aneuploidy early in pregnancy and give them the option to pursue invasive testing in a timely manner if desired.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Melissa L. Russo, Karin J. Blakemore,